Comparative optic and dosimetric characterization of the HYPERSCINT scintillation dosimetry research platform for multipoint applications
This study introduces the HYPERSCINT research platform (HYPERSCINT-RP100, Medscint Inc., Quebec, Canada), the first commercially available scintillation dosimetry platform capable of multi-point dosimetry through the hyperspectral approach.